Dasatinib in Treating Patients with Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Solar Melanoma that Cannot Be Removed by Surgery

December 18, 2009

The aim of this clinical trial is to study how well dasatinib works in treating patients with locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery.

Study Type: Interventional

Age/Sex Requirement: 18 years+ (None)

Sponsor: Eastern Cooperative Oncology Group

ClinicalTrials.gov Identifier: NCT00700882

Purpose: To study how well dasatinib works in treating patients with locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery. The primary outcome measure is objective tumor response rate. Secondary outcomes measures include response duration, progression-free survival, and safety profile.

Click here for more information about the clinical trial.